Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in Ankylosing Spondylitis
NCT00432653Phase 3Unknown
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Mar 2007
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of rituximab in ankylosing spondylitis (AS), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Assessment of SpondyloArthritis international Society 20% response at 24 weeks. Status: unknown.
02
Drugs
rituximab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT00432653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00432653.